LouisCarltonKirbyIIMD

Neurology • Paradise Valley, AZ

Consultant to Pharma on CNS drug and device development

Join to view full profile

Dr. Kirby is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kirby's full profile

Already have an account?

Office
2700 noplace
Paradise Valley, AZ 85253

Summary

I am a consultant for the pharmaceutical industry specializing in developing drugs and devices for CNS indications including Alzheimer's, Parkinson's disease and ALS. Board certified in neurology. Executive experience as founder and CEO of own medical research company, board of directors of largest regional chain of hospitals and Chief Medical Officer in a medical device company. Also writes novels as hobby. His first book Shadow of Eden has been an Amazon bestseller.

Education & Training

University of Texas Medical Branch HospitalsResidency, Neurology, 1981 - 1985
University of Texas Medical Branch School of MedicineClass of 1981

Certifications & Licensure

AZ State Medical License 1985 - 2027
TX State Medical License 1982 - 1988
American Board of Psychiatry and Neurology Neurology

Publications & Presentations

PubMed

Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study.
Stewart J Tepper, Detlef Albrecht, Jessica Ailani, Louis Kirby, Shannon Strom
CNS Drugs. 2024-12-01
48 citations
Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moder...
Carol Addy, Chris Assaid, David Hreniuk, Mark Stroh, Yang Xu
Journal of Clinical Pharmacology. 2009-07-01

Press Mentions

Cortexyme Assembles World Class Clinical Advisory Board to Support Its Alzheimer’s Disease Clinical Development ProgramSeptember 27th, 2018